Propanc Biopharma announced its key scientific data was published in a peer-reviewed journal showing.
Propanc Biopharma (OTCQB:PPCB) announced its key scientific data was published in a peer-reviewed journal showing.
As quoted in the press release:
Of particular note in the publication is the evaluation of clinical efficacy of a suppository formulation of pancreatic proenzymes in the context of a UK Pharmaceutical Specials Scheme, led by Dr Kenyon, where 19 from 46 patients (41.3%) with late stage cancers, most suffering from metastases, had a survival time significantly longer than the expected life span. For the whole set of cancer types, a mean survival of 9.0 months was significantly higher than their mean life expectancy, 5.6 months, in a one way ANOVA test (alpha = 0.05, P less than 0.05).
“We are delighted that our latest scientific paper shows the synergistic effects of our PRP formulation, which is proven to inhibit in vitroangiogenesis, tumour growth, cancer cell migration and invasiveness, and to be an effective and well tolerated in vivo anti-tumor treatment,” said Dr Julian Kenyon, Propanc Biopharma’s Chief Executive Officer.